Michael J. Keating

95.6k total citations · 21 hit papers
1.1k papers, 66.6k citations indexed

About

Michael J. Keating is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Michael J. Keating has authored 1.1k papers receiving a total of 66.6k indexed citations (citations by other indexed papers that have themselves been cited), including 711 papers in Genetics, 400 papers in Pathology and Forensic Medicine and 350 papers in Hematology. Recurrent topics in Michael J. Keating's work include Chronic Lymphocytic Leukemia Research (677 papers), Lymphoma Diagnosis and Treatment (388 papers) and Acute Myeloid Leukemia Research (227 papers). Michael J. Keating is often cited by papers focused on Chronic Lymphocytic Leukemia Research (677 papers), Lymphoma Diagnosis and Treatment (388 papers) and Acute Myeloid Leukemia Research (227 papers). Michael J. Keating collaborates with scholars based in United States, United Kingdom and Italy. Michael J. Keating's co-authors include Hagop M. Kantarjian, Susan O’Brien, William G. Wierda, Emil J. Freireich, William Plunkett, Elihu H. Estey, Jörge E. Cortes, Francis J. Giles, Susan Lerner and Maher Albitar and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael J. Keating

1.1k papers receiving 64.6k citations

Hit Papers

Frequent deletions and down-regulation of micro- RNA... 1986 2026 1999 2012 2002 2008 2018 1997 2011 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
    2002 3.9k citations George A. Calin, Calin Dan Dumitru et al. Proceedings of the National Academy of Sciences profile →
  2. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
    2008 2.2k citations Federico Caligaris‐Cappio, Michael J. Keating et al. Blood profile →
  3. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
    2018 971 citations Federico Caligaris‐Cappio, Michael J. Keating et al. Blood profile →
  4. Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
    1997 909 citations Elihu H. Estey, Maher Albitar et al. Blood profile →
  5. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
    2011 794 citations Michael J. Keating et al. profile →
  6. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    1998 738 citations Michael J. Keating et al. Journal of Clinical Oncology profile →
  7. Superoxide dismutase as a target for the selective killing of cancer cells
    2000 722 citations Michael J. Keating, William Plunkett et al. profile →
  8. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    2002 707 citations Michael J. Keating, Maher Albitar et al. Blood profile →
  9. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
    2005 704 citations Michael J. Keating, Susan O’Brien et al. Journal of Clinical Oncology profile →
  10. Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia
    2005 699 citations Michael J. Keating et al. profile →
  11. ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
    2004 659 citations Laura Z. Rassenti, Michael J. Keating et al. profile →
  12. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
    1990 617 citations Michael J. Keating et al. Journal of Clinical Oncology profile →
  13. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
    2000 586 citations Hagop M. Kantarjian, Jörge E. Cortes et al. Journal of Clinical Oncology profile →
  14. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    2000 559 citations Álvaro Aguayo, Hagop M. Kantarjian et al. Blood profile →
  15. Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes
    1987 509 citations Michael J. Keating et al. profile →
  16. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    2008 508 citations Constantine S. Tam, Susan O’Brien et al. Blood profile →
  17. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
    2011 499 citations Kumudha Balakrishnan, Varsha Gandhi et al. Blood profile →
  18. Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia
    1986 488 citations Hagop M. Kantarjian, Michael J. Keating et al. profile →
  19. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →
  20. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
    2016 431 citations Michael J. Keating et al. profile →
  21. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
    2015 350 citations Philip A. Thompson, Constantine S. Tam et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael J. Keating United States 121 30.8k 21.4k 21.3k 21.1k 14.7k 1.1k 66.6k
Hartmut Döhner Germany 101 19.0k 0.6× 17.5k 0.8× 21.1k 1.0× 12.1k 0.6× 9.5k 0.6× 653 44.9k
Donna Neuberg United States 113 9.4k 0.3× 14.4k 0.7× 12.4k 0.6× 11.3k 0.5× 9.5k 0.6× 719 46.3k
Brian Druker United States 106 21.7k 0.7× 17.1k 0.8× 30.5k 1.4× 3.9k 0.2× 5.8k 0.4× 607 54.8k
Michael Andreeff United States 112 10.3k 0.3× 25.9k 1.2× 16.0k 0.8× 3.5k 0.2× 7.1k 0.5× 1.0k 48.1k
Kenneth C. Anderson United States 139 7.8k 0.3× 47.4k 2.2× 42.0k 2.0× 7.5k 0.4× 11.7k 0.8× 1.4k 76.9k
Razelle Kurzrock United States 119 6.8k 0.2× 21.0k 1.0× 6.9k 0.3× 10.0k 0.5× 8.2k 0.6× 1.2k 60.4k
Charles L. Sawyers United States 99 11.6k 0.4× 24.8k 1.2× 15.8k 0.7× 3.4k 0.2× 3.2k 0.2× 266 53.4k
Michelle M. Le Beau United States 82 7.4k 0.2× 16.9k 0.8× 15.6k 0.7× 3.2k 0.2× 5.1k 0.3× 347 35.2k
Benjamin L. Ebert United States 78 9.0k 0.3× 46.7k 2.2× 14.2k 0.7× 3.2k 0.2× 9.5k 0.6× 294 73.5k
Robert A. Kyle United States 125 12.5k 0.4× 35.1k 1.6× 34.0k 1.6× 5.5k 0.3× 4.3k 0.3× 1.0k 59.9k

Countries citing papers authored by Michael J. Keating

Since Specialization
Citations

This map shows the geographic impact of Michael J. Keating's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Keating with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Keating more than expected).

Fields of papers citing papers by Michael J. Keating

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Keating. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Keating. The network helps show where Michael J. Keating may publish in the future.

Co-authorship network of co-authors of Michael J. Keating

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Keating. A scholar is included among the top collaborators of Michael J. Keating based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Keating. Michael J. Keating is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gordon, Max J., Jade Jones, Binsah George, et al.. (2023). Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 129(14). 2192–2200. 10 indexed citations
2.
Sarkar, Aloke, Görkem Kısmalı, Burcu Aslan, et al.. (2020). AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(14). 3856–3867. 43 indexed citations
3.
Zhang, Ronghua, Cristina Ivan, Giovanni Galletti, et al.. (2019). Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunology Research. 7(12). 2036–2051. 38 indexed citations
4.
Vangapandu, Hima V., Ondřej Havránek, Mary Ayres, et al.. (2017). B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Molecular Cancer Research. 15(12). 1692–1703. 40 indexed citations
5.
Rozovski, Uri, David Harris, Ping Li, et al.. (2017). Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex. Molecular Cancer Research. 15(5). 610–618. 23 indexed citations
6.
Vitale, Candida, Lorenzo Falchi, Elisa ten Hacken, et al.. (2016). Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical Cancer Research. 22(10). 2359–2367. 23 indexed citations
7.
Patel, Viralkumar, Kumudha Balakrishnan, Елена Бибикова, et al.. (2016). Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 23(14). 3734–3743. 109 indexed citations
8.
Jain, Preetesh, Michael J. Keating, William G. Wierda, et al.. (2016). Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(9). 2154–2158. 45 indexed citations
9.
Lamothe, Betty, William G. Wierda, Michael J. Keating, & Varsha Gandhi. (2016). Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clinical Cancer Research. 22(18). 4712–4726. 22 indexed citations
10.
Cervantes-Gomez, Fabiola, Betty Lamothe, Jennifer A. Woyach, et al.. (2015). Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 21(16). 3705–3715. 161 indexed citations
11.
Rozovski, Uri, Srđana Grgurević, Carlos Bueso-Ramos, et al.. (2015). Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Molecular Cancer Research. 13(5). 944–953. 69 indexed citations
12.
Badoux, Xavier C., Michael J. Keating, Sijin Wen, et al.. (2012). Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 31(5). 584–591. 113 indexed citations
13.
Hoellenriegel, Julia, Sarah Meadows, Mariela Sivina, et al.. (2011). The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118(13). 3603–3612. 442 indexed citations breakdown →
14.
15.
Tam, Constantine S., Tait D. Shanafelt, William G. Wierda, et al.. (2009). De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 114(5). 957–964. 114 indexed citations
16.
Tsai, Cheng‐Yu, Adrian S. Ray, Daniel B. Tumas, et al.. (2009). Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219. Clinical Cancer Research. 15(11). 3760–3769. 11 indexed citations
17.
Ma, Wanlong, Hagop M. Kantarjian, B. Nebiyou Bekele, et al.. (2009). Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome. Clinical Cancer Research. 15(11). 3820–3826. 40 indexed citations
18.
Ferrajoli, Alessandra, Bang-Ning Lee, Ellen Schlette, et al.. (2008). Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 111(11). 5291–5297. 304 indexed citations
19.
Calin, George A., Calin Dan Dumitru, Masayoshi Shimizu, et al.. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences. 99(24). 15524–15529. 3875 indexed citations breakdown →
20.
Aguayo, Álvaro, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (1999). Complete hematologic and cytogenetic response to 2-amino-9-?-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase. Cancer. 85(1). 58–64. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hartmut Döhner Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Michael Andreeff Breakdown of academic impact, for papers by Kenneth C. Anderson Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Charles L. Sawyers Breakdown of academic impact, for papers by Michelle M. Le Beau Breakdown of academic impact, for papers by Benjamin L. Ebert Breakdown of academic impact, for papers by Robert A. Kyle
Rankless by CCL
2026